Shares of PaxMedica, Inc. (NASDAQ:PXMD – Get Free Report) rose 9% during trading on Friday . The company traded as high as $0.12 and last traded at $0.12. Approximately 27,273 shares traded hands during trading, a decline of 97% from the average daily volume of 784,475 shares. The stock had previously closed at $0.11.
PaxMedica Stock Performance
The business’s 50 day simple moving average is $0.12 and its 200 day simple moving average is $0.24.
PaxMedica (NASDAQ:PXMD – Get Free Report) last issued its earnings results on Friday, September 20th. The company reported ($0.39) EPS for the quarter.
About PaxMedica
PaxMedica, Inc, a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome.
See Also
- Five stocks we like better than PaxMedica
- What Does Downgrade Mean in Investing?
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- What is a Dividend King?
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- Differences Between Momentum Investing and Long Term Investing
- Battle of the Retailers: Who Comes Out on Top?
Receive News & Ratings for PaxMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PaxMedica and related companies with MarketBeat.com's FREE daily email newsletter.
